Literature DB >> 34019641

The clinical and functional effects of TERT variants in myelodysplastic syndrome.

Christopher R Reilly1, Mikko Myllymäki1, Robert Redd2, Shilpa Padmanaban3, Druha Karunakaran1, Valerie Tesmer3, Frederick D Tsai1, Christopher J Gibson1, Huma Q Rana4, Liang Zhong5,6, Wael Saber7, Stephen R Spellman8, Zhen-Huan Hu7, Esther H Orr9, Maxine M Chen9, Immaculata De Vivo9,10, Daniel J DeAngelo1, Corey Cutler1, Joseph H Antin1, Donna Neuberg2, Judy E Garber4, Jayakrishnan Nandakumar3, Suneet Agarwal5,6, R Coleman Lindsley1.   

Abstract

Germline pathogenic TERT variants are associated with short telomeres and an increased risk of developing myelodysplastic syndrome (MDS) among patients with a telomere biology disorder. We identified TERT rare variants in 41 of 1514 MDS patients (2.7%) without a clinical diagnosis of a telomere biology disorder who underwent allogeneic transplantation. Patients with a TERT rare variant had shorter telomere length (P < .001) and younger age at MDS diagnosis (52 vs 59 years, P = .03) than patients without a TERT rare variant. In multivariable models, TERT rare variants were associated with inferior overall survival (P = .034) driven by an increased incidence of nonrelapse mortality (NRM; P = .015). Death from a noninfectious pulmonary cause was more frequent among patients with a TERT rare variant. Most variants were missense substitutions and classified as variants of unknown significance. Therefore, we cloned all rare missense variants and quantified their impact on telomere elongation in a cell-based assay. We found that 90% of TERT rare variants had severe or intermediate impairment in their capacity to elongate telomeres. Using a homology model of human TERT bound to the shelterin protein TPP1, we inferred that TERT rare variants disrupt domain-specific functions, including catalysis, protein-RNA interactions, and recruitment to telomeres. Our results indicate that the contribution of TERT rare variants to MDS pathogenesis and NRM risk is underrecognized. Routine screening for TERT rare variants in MDS patients regardless of age or clinical suspicion may identify clinically inapparent telomere biology disorders and improve transplant outcomes through risk-adapted approaches.
© 2021 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34019641      PMCID: PMC8432045          DOI: 10.1182/blood.2021011075

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   25.476


  66 in total

1.  Involvement of 14-3-3 proteins in nuclear localization of telomerase.

Authors:  H Seimiya; H Sawada; Y Muramatsu; M Shimizu; K Ohko; K Yamane; T Tsuruo
Journal:  EMBO J       Date:  2000-06-01       Impact factor: 11.598

2.  Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia.

Authors:  Rodrigo T Calado; Joshua A Regal; Mark Hills; William T Yewdell; Leandro F Dalmazzo; Marco A Zago; Peter M Lansdorp; Donna Hogge; Stephen J Chanock; Elihu H Estey; Roberto P Falcão; Neal S Young
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-15       Impact factor: 11.205

Review 3.  Survival after Hematopoietic Stem Cell Transplant in Patients with Dyskeratosis Congenita: Systematic Review of the Literature.

Authors:  Pasquale Barbaro; Aditi Vedi
Journal:  Biol Blood Marrow Transplant       Date:  2016-03-08       Impact factor: 5.742

4.  A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies.

Authors:  Steffen Boettcher; Peter G Miller; Rohan Sharma; Marie McConkey; Matthew Leventhal; Andrei V Krivtsov; Andrew O Giacomelli; Waihay Wong; Jesi Kim; Sherry Chao; Kari J Kurppa; Xiaoping Yang; Kirsten Milenkowic; Federica Piccioni; David E Root; Frank G Rücker; Yael Flamand; Donna Neuberg; R Coleman Lindsley; Pasi A Jänne; William C Hahn; Tyler Jacks; Hartmut Döhner; Scott A Armstrong; Benjamin L Ebert
Journal:  Science       Date:  2019-08-09       Impact factor: 47.728

5.  Syndrome complex of bone marrow failure and pulmonary fibrosis predicts germline defects in telomerase.

Authors:  Erin M Parry; Jonathan K Alder; Xiaodong Qi; Julian J-L Chen; Mary Armanios
Journal:  Blood       Date:  2011-03-24       Impact factor: 22.113

6.  C-terminal regions of the human telomerase catalytic subunit essential for in vivo enzyme activity.

Authors:  Soma S R Banik; Chuanhai Guo; Allyson C Smith; Seth S Margolis; D Ashley Richardson; Carlos A Tirado; Christopher M Counter
Journal:  Mol Cell Biol       Date:  2002-09       Impact factor: 4.272

7.  Adult-onset pulmonary fibrosis caused by mutations in telomerase.

Authors:  Kalliopi D Tsakiri; Jennifer T Cronkhite; Phillip J Kuan; Chao Xing; Ganesh Raghu; Jonathan C Weissler; Randall L Rosenblatt; Jerry W Shay; Christine Kim Garcia
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-25       Impact factor: 11.205

8.  Heterozygous RTEL1 variants in bone marrow failure and myeloid neoplasms.

Authors:  Judith C W Marsh; Fernanda Gutierrez-Rodrigues; James Cooper; Jie Jiang; Shreyans Gandhi; Sachiko Kajigaya; Xingmin Feng; Maria Del Pilar F Ibanez; Flávia S Donaires; João P Lopes da Silva; Zejuan Li; Soma Das; Maria Ibanez; Alexander E Smith; Nicholas Lea; Steven Best; Robin Ireland; Austin G Kulasekararaj; Donal P McLornan; Anthony Pagliuca; Isabelle Callebaut; Neal S Young; Rodrigo T Calado; Danielle M Townsley; Ghulam J Mufti
Journal:  Blood Adv       Date:  2018-01-04

9.  Evaluation of in silico algorithms for use with ACMG/AMP clinical variant interpretation guidelines.

Authors:  Rajarshi Ghosh; Ninad Oak; Sharon E Plon
Journal:  Genome Biol       Date:  2017-11-28       Impact factor: 13.583

10.  Cryo-EM structure of substrate-bound human telomerase holoenzyme.

Authors:  Thi Hoang Duong Nguyen; Jane Tam; Robert A Wu; Basil J Greber; Daniel Toso; Eva Nogales; Kathleen Collins
Journal:  Nature       Date:  2018-04-25       Impact factor: 49.962

View more
  6 in total

1.  Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML.

Authors:  H Moses Murdock; Haesook T Kim; Nathan Denlinger; Pankit Vachhani; Bryan Hambley; Bryan S Manning; Shannon Gier; Christina Cho; Harrison K Tsai; Shannon McCurdy; Vincent T Ho; John Koreth; Robert J Soiffer; Jerome Ritz; Martin P Carroll; Sumithira Vasu; Miguel-Angel Perales; Eunice S Wang; Lukasz P Gondek; Steven Devine; Edwin P Alyea; R Coleman Lindsley; Christopher J Gibson
Journal:  Blood       Date:  2022-06-16       Impact factor: 25.476

2.  Structure of active human telomerase with telomere shelterin protein TPP1.

Authors:  Baocheng Liu; Yao He; Yaqiang Wang; He Song; Z Hong Zhou; Juli Feigon
Journal:  Nature       Date:  2022-04-13       Impact factor: 69.504

Review 3.  Lessons From Pediatric MDS: Approaches to Germline Predisposition to Hematologic Malignancies.

Authors:  Serine Avagyan; Akiko Shimamura
Journal:  Front Oncol       Date:  2022-03-09       Impact factor: 6.244

Review 4.  Telomere-mediated lung disease.

Authors:  Jonathan K Alder; Mary Armanios
Journal:  Physiol Rev       Date:  2022-05-09       Impact factor: 46.500

5.  Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis.

Authors:  Siddhartha P Kar; Pedro M Quiros; Muxin Gu; Tao Jiang; Jonathan Mitchell; Ryan Langdon; Vivek Iyer; Clea Barcena; M S Vijayabaskar; Margarete A Fabre; Paul Carter; Slavé Petrovski; Stephen Burgess; George S Vassiliou
Journal:  Nat Genet       Date:  2022-07-14       Impact factor: 41.307

6.  Somatic reversion impacts myelodysplastic syndromes and acute myeloid leukemia evolution in the short telomere disorders.

Authors:  Kristen E Schratz; Valeriya Gaysinskaya; Zoe L Cosner; Emily A DeBoy; Zhimin Xiang; Laura Kasch-Semenza; Liliana Florea; Pali D Shah; Mary Armanios
Journal:  J Clin Invest       Date:  2021-09-15       Impact factor: 14.808

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.